FASN and metabolic dysfunction-associated steatotic liver disease: The NF-κB/MyD88 pathway drives inflammasome activation, which is a cytosolic regulator of inflammation that, through the caspase-2 pathway, activates SREBP1c to induce ACC-1 and FASN, contributing to the exacerbation of hepatic steatosis and inflammation in NAFLD [97].